- Home
- GLPG vs GLP Comparison
GLPG vs GLP Comparison
Compare GLPG & GLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- GLP
- Stock Information
- Founded
- GLPG 1999
- GLP 2005
- Country
- GLPG Belgium
- GLP United States
- Employees
- GLPG N/A
- GLP N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- GLP Oil Refining/Marketing
- Sector
- GLPG Health Care
- GLP Energy
- Exchange
- GLPG Nasdaq
- GLP Nasdaq
- Market Cap
- GLPG 2.1B
- GLP 1.8B
- IPO Year
- GLPG 2005
- GLP 2005
- Fundamental
- Price
- GLPG $33.24
- GLP $50.73
- Analyst Decision
- GLPG Sell
- GLP Hold
- Analyst Count
- GLPG 3
- GLP 1
- Target Price
- GLPG $26.00
- GLP $56.00
- AVG Volume (30 Days)
- GLPG 162.5K
- GLP 80.5K
- Earning Date
- GLPG 10-29-2025
- GLP 11-07-2025
- Dividend Yield
- GLPG N/A
- GLP 5.87%
- EPS Growth
- GLPG N/A
- GLP N/A
- EPS
- GLPG N/A
- GLP 2.60
- Revenue
- GLPG $323,674,692.00
- GLP $17,827,598,000.00
- Revenue This Year
- GLPG $1.77
- GLP $37.98
- Revenue Next Year
- GLPG N/A
- GLP $28.27
- P/E Ratio
- GLPG N/A
- GLP $19.65
- Revenue Growth
- GLPG 5.43
- GLP 3.74
- 52 Week Low
- GLPG $22.36
- GLP $42.88
- 52 Week High
- GLPG $33.86
- GLP $60.00
- Technical
- Relative Strength Index (RSI)
- GLPG 58.22
- GLP 44.20
- Support Level
- GLPG $31.49
- GLP $50.88
- Resistance Level
- GLPG $33.63
- GLP $51.79
- Average True Range (ATR)
- GLPG 0.68
- GLP 1.19
- MACD
- GLPG 0.01
- GLP -0.17
- Stochastic Oscillator
- GLPG 85.82
- GLP 13.70
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About GLP Global Partners LP Common Units representing Limited Partner Interests
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the Wholesale segment.